Skip to main content
OpenTrials
Completed

NCT Number: NCT05643326

At Home Gamma tACS in Alzheimer's Disease (tACS@Home)

Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as "oscillopathies". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.

Transcranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory.

On the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.

In this randomized, double-blind, sham-controlled study, followed by an open-label phase, the investigators will evaluate whether a 9- or 18-weeks treatment with gamma tACS over the precuneus, delivered at home, can improve symptoms in patients with mild Alzheimer's disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ASST Spedali Civili di Brescia

Brescia, BS, 25123, Italy

About this study

Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as "oscillopathies". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.

Transcranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory.

On the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.

In this randomized, double-blind, sham-controlled study, followed by an open-label phase, the investigators will evaluate whether a 9- or 18-weeks treatment with gamma tACS over the precuneus, delivered at home, can improve symptoms in patients with mild Alzheimer's disease.

Subjects will be randomized in two groups in the first part of the trial. One group will receive a two-months treatment with gamma tACS (40 Hz) over the precuneus while the other group will receive placebo (sham) stimulation. After two-months, both group will undergo real stimulation (open-label phase) with gamma tACS (40 Hz) over the precuneus for two-months. Modulators of response will be considered.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for the Patient:

  • Mild Alzheimer's disease (CDR 0.5 - 1)

Exclusion criteria

for the Patient:

  • Cerebrovascular disorders
  • Previous stroke
  • Hydrocephalus
  • Intra-cranial mass documented by MRI
  • History of traumatic brain injury or other neurological diseases
  • Serious medical illness other than AD
  • History of seizures
  • Pregnancy
  • Metal implants in the head (except dental fillings)
  • Electronic implants (i.e. pace-maker, implanted medical pump)
  • Age <18 years

Inclusion criteria

for the Caregiver:

  • Age > 18 years
  • Compliance in participation in training on the use of the therapeutic device
  • Mini-Mental State Examination >26/30

Treatment and study plan

40 Hz transcranial alternating current stimulation

Device

42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)

Sham stimulation

Device

42 sessions of sham stimulation (5 days/week for 9 weeks)

Primary outcomes

  1. Safety of transcranial alternating current stimulation delivered at home

    Time frame: Through study completion, at week 24

    Incidence of Treatment-Emergent Adverse Events as assessed by the incidence of adverse events graded from 1 (mild) to 5 (fatal).

  2. Tolerability of transcranial alternating current stimulation delivered at home

    Time frame: Through study completion, at week 24

    Tolerability will be evaluated with percentage of compliance (number of delivered stimulations divided by number of programmed stimulations times one-hundred). The primary outcome will be reached if compliance will be >90%.

  3. Changes in Clinical Dementia Rating scale (CDR) sum of boxes

    Time frame: Difference between treatments (real and sham) at week 8

    CDR-SB scores range from 0 to 18, with higher scores indicating worse cognition and daily function.

  4. Changes in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog)13

    Time frame: Difference between treatments (real and sham) at week 8

    ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit.

  5. Changes in Face-Name Associative Memory Test (FNAT) scores

    Time frame: Difference between treatments (real and sham) at week 8

    The Face-Name Associative Memory Test is a cross-modal associative memory test, it includes 20 face-name pairs. The administration procedure starts with the presentation of 20 faces with each name and participants should read the name underneath the faces and try to learn each face-name pair. After 5 minutes, the faces are shown one by one and participants are asked to recall the associated names from 4 different names. The correct number of pairs recalled is recorded. The score ranges from 0 (worse performance) to 20 (best performance).

  6. Changes in Alzheimer's Disease Assessment Scale Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

    Time frame: Difference between treatments (real and sham) at week 8

    ADCS-ADL scores range from 0 to 78, with lower scores indicating greater functional impairment.

Secondary outcomes

  1. Changes in Clinical Dementia Rating scale (CDR) sum of boxes

    Time frame: Change from baseline to week 8 - 16 - 24

    CDR-SB scores range from 0 to 18, with higher scores indicating worse cognition and daily function.

  2. Changes in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog)13

    Time frame: Change from baseline to week 8 - 16 - 24

    ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit.

  3. Changes in Rey Auditory Verbal Learning Test scores

    Time frame: Change from baseline to week 8 - 16 - 24

    Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes. The score ranges from 0 (worse performance) to 15 (best performance).

  4. Changes in Face-Name Associative Memory Test (FNAT) scores

    Time frame: Change from baseline to week 8 - 16 - 24

    The Face-Name Associative Memory Test is a cross-modal associative memory test, it includes 20 face-name pairs. The administration procedure starts with the presentation of 20 faces with each name and participants should read the name underneath the faces and try to learn each face-name pair. After 5 minutes, the faces are shown one by one and participants are asked to recall the associated names from 4 different names. The correct number of pairs recalled is recorded. The score ranges from 0 (worse performance) to 20 (best performance).

  5. Changes in the Neuropsychiatric Inventory (NPI-Q)

    Time frame: Change from baseline to week 8 - 16 - 24

    The NPI-Q is designed to be an informant-based interview that assesses neuropsychiatric symptoms of the participant over the previous month. The score ranges from 0 (no symptoms) to 180 (severe symptoms).

  6. Changes in Caregiver Burden Inventory (CBI)

    Time frame: Change from baseline to week 8 - 16 - 24

    The Caregiver Burden Inventory (CBI) includes 24 items and 5 dimensions: Time-dependence, developmental, physical, emotional, and social burden. There are 5 items for each dimension, except for the physical dimension, which has four items. Each item signifies a score between zero (not descriptive) and four (highly descriptive), with a higher score indicating greater care burden. Therefore the total score for time-dependence, developmental, emotional, and social burden range from 0 to 20 except for physical burden where scores range from 0 to 16. The total score ranges from 0 (no burden) to 96 (severe burden).

  7. Changes in Alzheimer's Disease Assessment Scale Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

    Time frame: Change from baseline to week 8 - 16 - 24

    ADCS-ADL scores range from 0 to 78, with lower scores indicating greater functional impairment.

  8. Change in SAI measurements

    Time frame: Change from baseline to week 8 - 16 - 24

    By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic transmission. SAI is expressed as % of the unconditioned motor evoked potential.

  9. Change in EEG gamma power

    Time frame: Change from baseline to week 8 - 16 - 24

    By using electroencephalography (EEG), the investigators will evaluate the change in gamma power.

  10. Change in plasma NfL levels

    Time frame: Change from baseline to week 8 - 16 - 24

    Changes in plasma neurofilament light (NfL) levels (pg/mL) will be evaluated.

  11. Change in plasma GFAP levels

    Time frame: Change from baseline to week 8 - 16 - 24

    Changes in plasma glial fibrillary acidic protein (GFAP) levels (pg/mL) will be evaluated.

  12. Change in plasma amyloid beta1-40 levels

    Time frame: Change from baseline to week 8 - 16 - 24

    Change in plasma amyloid beta1-40 levels (pg/mL) will be evaluated.

  13. Change in plasma amyloid beta1-42 levels

    Time frame: Change from baseline to week 8 - 16 - 24

    Change in plasma amyloid beta1-42 levels (pg/mL) will be evaluated.

  14. Change in plasma pTau217

    Time frame: Change from baseline to week 8 - 16 - 24

    Change in plasma pTau217 levels (pg/mL) will be evaluated.

  15. Change in resting state MRI connectivity

    Time frame: Change from baseline to week 8

    Change in resting state magnetic resonance imaging connectivity (default mode network) both static and dynamic.

  16. Change in plasma TMT part B scores

    Time frame: Change from baseline to week 8 - 16 - 24

    The Trail Making Test Part B consists of 24 circles on a piece of paper, but rather than all of the circles containing numbers, half of the circles have the numbers 1-12 in them and the other half (12) contain the letters A-L. The person taking the test has to draw a line from one circle to the next in ascending order; however, he must alternate the circles with numbers in them (1-13) with circles with letters in them (A-L). In other words, he is to connect the circles in order like this: 1-A-2-B-3-C-4-D-5-E and so on. Scoring is based on time taken to complete the test with lower scores being better.

  17. Changes in semantic fluency task

    Time frame: Change from baseline to week 8 - 16 - 24

    In the semantic fluency task, participants are asked to generate as many words as possible from a given category (animals) within a limited time (60 seconds); lower scores indicate greater impairment in verbal fluency.

Sponsors and collaborators

Lead sponsor

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Other

Registry information

Official study title

Markers of Clinical and Biological Response to Home Delivered Transcranial Alternating Current Stimulation (tACS) in Patients With Alzheimer's Disease

Acronym: tACS@Home

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Dec 8, 2022
Registry last updated
Apr 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.